Letter to the Editor Regarding ‘Bone metastasis of limb segments: Is mesometastasis another poor prognostic factor of cancer patients?’

2020 ◽  
Vol 50 (10) ◽  
pp. 1225-1225
Author(s):  
Shihong Ren ◽  
Zhan Wang
Keyword(s):  
Bone Metastasis ◽  
Prognostic Factor ◽  
Cancer Patients ◽  
Poor Prognostic Factor ◽  
Letter To The Editor

Author’s reply to ‘bone metastasis of limb segments: is mesometastasis another poor prognostic factor of cancer patients?’

2020 ◽  
Vol 50 (10) ◽  
pp. 1226-1226
Author(s):  
Shoichiro Tani ◽  
Yutaka Morizaki ◽  
Kosuke Uehara ◽  
Ryoko Sawada ◽  
Hiroshi Kobayashi ◽  
...  
Keyword(s):  
Bone Metastasis ◽  
Prognostic Factor ◽  
Cancer Patients ◽  
Poor Prognostic Factor

scholarly journals Bone metastasis of limb segments: Is mesometastasis another poor prognostic factor of cancer patients?

2020 ◽  
Vol 50 (6) ◽  
pp. 688-692
Author(s):  
Shoichiro Tani ◽  
Yutaka Morizaki ◽  
Kosuke Uehara ◽  
Ryoko Sawada ◽  
Hiroshi Kobayashi ◽  
...  
Keyword(s):  
Bone Metastasis ◽  
Prognostic Factor ◽  
Bone Metastases ◽  
Cancer Patients ◽  
Survival Curve ◽  
Lower Leg ◽  
Poor Prognostic Factor ◽  
Significant Difference ◽  
The University ◽  
Distal Site

Abstract Objective In contrast to acrometastasis, defined as bone metastasis to the hand or foot, the frequency and prognosis of bone metastasis of other limb segments remain unclear. To compare prognosis according to sites of bone metastasis, we defined two new terms in this study: ‘mesometastasis’ and ‘rhizometastasis’ as bone metastasis of ‘forearm or lower leg’ and ‘arm or thigh’, respectively. Methods A total of 539 patients who were registered to the bone metastasis database of The University of Tokyo Hospital from April 2012 to May 2016 were retrospectively surveyed. All patients who were diagnosed to have bone metastases in our hospital are registered to the database. Patients were categorized into four groups according to the most distal site of bone metastases: ‘acrometastasis’, ‘mesometastasis’, ‘rhizometastasis’ and ‘body trunk metastasis’. Results The frequency of rhizometastasis (22.5%) or body trunk metastasis (73.1%) was significantly higher than that of acrometastasis (2.0%) or mesometastasis (2.4%). The median survival time after diagnosis of bone metastases for each group was as follows: 6.5 months in acrometastasis, 4.0 months in mesometastasis, 16 months in rhizometastasis, 17 months in body trunk metastasis and 16 months overall. In survival curve, there was a statistically significant difference between mesometastasis and body trunk metastasis. Conclusions Our findings suggest that ‘mesometastasis’ could be another poor prognostic factor in cancer patients and that patients with mesometastasis should receive appropriate treatments according to their expected prognosis.

scholarly journals Bone Scan Index Is a Prognostic Factor for Breast Cancer Patients with Bone Metastasis Being Treated with Zoledronic Acid

2015 ◽  
Vol 05 (03) ◽  
pp. 149-158
Author(s):  
Yukinori Okada ◽  
Tatsuyuki Abe ◽  
Yasuo Nakajima ◽  
Itsuko Okuda ◽  
Brandon D. Lohman ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Zoledronic Acid ◽  
Bone Metastasis ◽  
Prognostic Factor ◽  
Cancer Patients ◽  
Bone Scan ◽  
Breast Cancer Patients ◽  
Bone Scan Index

scholarly journals Size of pelvic bone metastasis as a significant prognostic factor for metastatic prostate cancer patients

2020 ◽  
Vol 38 (10) ◽  
pp. 993-996
Author(s):  
Toyokazu Hayakawa ◽  
Ken-ichi Tabata ◽  
Hideyasu Tsumura ◽  
Shogo Kawakami ◽  
Takeo Katakura ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Bone Metastasis ◽  
Prognostic Factor ◽  
Cancer Patients ◽  
Metastatic Prostate Cancer ◽  
Pelvic Bone ◽  
Significant Prognostic Factor
Sign in / Sign up

Export Citation Format

Share Document